Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
-
Published:2018-05
Issue:5
Volume:18
Page:353-360.e1
-
ISSN:2152-2650
-
Container-title:Clinical Lymphoma Myeloma and Leukemia
-
language:en
-
Short-container-title:Clinical Lymphoma Myeloma and Leukemia
Author:
Okada Masaya, Imagawa Jun, Tanaka Hideo, Nakamae Hirohisa, Hino Masayuki, Murai Kazunori, Ishida Yoji, Kumagai Takashi, Sato Seiichi, Ohashi Kazuteru, Sakamaki Hisashi, Wakita Hisashi, Uoshima Nobuhiko, Nakagawa Yasunori, Minami Yosuke, Ogasawara Masahiro, Takeoka TomoharuORCID, Akasaka Hiroshi, Utsumi Takahiko, Uike Naokuni, Sato Tsutomu, Ando Sachiko, Usuki Kensuke, Mizuta Syuichi, Hashino Satoshi, Nomura Tetsuhiko, Shikami Masato, Fukutani Hisashi, Ohe Yokiko, Kosugi Hiroshi, Shibayama Hirohiko, Maeda Yasuhiro, Fukushima Toshihiro, Yamazaki Hirohito, Tsubaki Kazuo, Kukita Toshimasa, Adachi Yoko, Nataduka Toshiki, Sakoda Hiroto, Yokoyama Hisayuki, Okamoto Takahiro, Shirasugi Yukari, Onishi Yasushi, Nohgawa Masaharu, Yoshihara Satoshi, Morita Satoshi, Sakamoto Junichi, Kimura Shinya
Subject
Cancer Research,Oncology,Hematology
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|